Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 35 Show results per page	View Search Criteria \| Help With Results

Last Modified: 6/12/2007 First Published: 3/1/2000


1.		Phase III Randomized Study of Homoharringtonine Versus Hydroxyurea in Patients With Interferon alfa Refractory Chronic Myelogenous Leukemia (Summary Last Modified 06/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				16 and over				NCI				CLB-19807 SWOG-C19807, NCT00004933, C19807


2.		Phase I/II Chemotherapy with Homoharringtonine for Refractory Acute Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				17 and over								MSKCC-82154 NCI-W83-0248, W83-0248

Last Modified: 11/1/2001


3.		Phase II Study of Homoharringtonine with Low Dose Cytarabine In Patients with Chronic Myelogenous Leukemia (Summary Last Modified 11/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				15 and over				NCI				MDA-DM-93144 NCI-T93-0192D, T93-0192

Last Modified: 10/1/2001


4.		Phase II Study of Homoharringtonine with IFN-A in Chronic Phase Chronic Myelogenous Leukemia (Summary Last Modified 10/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				15 and over				NCI				MDA-DM-93151 NCI-T93-0191D, NCT00002574, T93-0191

Last Modified: 11/1/2001


5.		Phase II Study of Low-Dose Cytarabine/Homoharringtonine for Chronic Myelogenous Leukemia in Chronic Phase (Summary Last Modified 11/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				over 18				NCI				DFCI-95005 NCI-T94-0199D, T94-0199

Last Modified: 5/1/2001 First Published: 4/1/1998


6.		Phase II Study of Cytarabine, Homoharringtonine, and Interferon Alfa for Early Chronic Phase Chronic Myelogenous Leukemia (Summary Last Modified 05/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				12 and over				NCI				MDA-DM-97229 MDA-FDR001791, NCI-T97-0105, NCT00003239, T97-0105

Last Modified: 11/12/2008 First Published: 2/1/1999


7.		Phase II Study of Homoharringtonine in Combination with Low Dose Cytarabine in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				CLB-19804 NCT00003694, CALGB-19804

Last Modified: 1/15/2007 First Published: 10/1/2000


8.		Phase II Pilot Study of Homoharringtonine in Patients With Chronic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				12 and over				NCI				MDA-ID-99032 MDA-FDR001783, NCI-T99-0044, T99-0044, NCT00006364

Last Modified: 11/20/2007


9.		Phase II Chemotherapy with Homoharringtonine for Metastatic Colorectal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 15								MDA-DM-8209 NCI-C83-0508

Last Modified: 11/20/2007


10.		Phase II Chemotherapy with 5-Day Intermittent Intravenous Homoharringtonine for Refractory Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				15 and over				NCI				MDA-DM-8241 NCI-T83-0903C, T83-0903

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute